https://doi.org/10.4081/aiua.2024.12404
Office-based management of Non-Muscle Invasive Bladder Cancer (NMIBC): A position paper on current state of the art and future perspectives
Submitted: February 20, 2024
Accepted: February 24, 2024
Published: March 19, 2024
Accepted: February 24, 2024
Abstract Views: 276
PDF: 214
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To the Editor,
Bladder cancer is one of the most common cancers in humans, representing the 7th and 17th type of neoplasm in both genders. Its incidence and mortality are quite heterogeneous in different countries and are due to different risk factors, quality and prevalence of healthcare and the possibility of early diagnosis and treatment of the tumor and its potential recurrences [...]
Siregar GP, Parwati I, Noegroho BS, et al. The association between serum hypoxia inducible factor-1α level and urothelial bladder cancer: A preliminary study. Arch Ital Urol Androl 2023;95:11292.
DOI: https://doi.org/10.4081/aiua.2023.11292
MacDonald A, Mehrnoush V, Ismail A, et al. History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer. Arch Ital Urol Androl 2023;95:11380.
DOI: https://doi.org/10.4081/aiua.2023.11380
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023..
Mantica G, Smelzo S, Ambrosini F, et al. Port-site metastasis and atypical recurrences after robotic-assisted radical cystectomy (RARC): an updated comprehensive and systematic review of current evidences. J Robot Surg 2020;14:805-12.
DOI: https://doi.org/10.1007/s11701-020-01062-x
Maffezzini M, Fontana V, Pacchetti A, et al. Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. Arch Ital Urol Androl 2021;93:15-20.
DOI: https://doi.org/10.4081/aiua.2021.1.15
Malinaric R, Mantica G, Balzarini F, et al. Extraperitoneal cystectomy with ureterocutaneostomy derivation in fragile patients - should it be performed more often? Arch Ital Urol Androl 2022;94:144-9.
DOI: https://doi.org/10.4081/aiua.2022.2.144
Slovacek H, Zhuo J, Taylor JM. Approaches to Non-Muscle-Invasive Bladder Cancer. Curr Oncol Rep 2021;23:105.
DOI: https://doi.org/10.1007/s11912-021-01091-1
Alvarez-Maestro M, Chierigo F, Mantica G, et al. The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: A systematic review. Arab J Urol 2021;20:1-13.
DOI: https://doi.org/10.1080/2090598X.2021.1994230
Joyce DD, Sharma V, Williams SB. Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature. Pharmacoeconomics 2023;41:751-69.
DOI: https://doi.org/10.1007/s40273-023-01273-8
Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol 2020;38:1895-904.
DOI: https://doi.org/10.1007/s00345-019-02984-4
Leonardi R, Bellinzoni P, Broglia L, et al. Hospital care in Departments defined as COVID-free: A proposal for a safe hospitalization protecting healthcare professionals and patients not affected by COVID-19. Arch Ital Urol Androl 2020;92:67.
DOI: https://doi.org/10.4081/aiua.2020.2.67
Soloway MS. Active Surveillance or Office Fulguration for Low Grade Ta Bladder Tumors: A Win-Win for Patients and Urologists. J Urol 2018;199:1120-2.
DOI: https://doi.org/10.1016/j.juro.2017.09.123
Xu Y, Guan W, Chen W, et al. Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: A prospective, randomized study. Lasers Surg Med 2015;47:306-11.
DOI: https://doi.org/10.1002/lsm.22342
Planelles Gómez J, Olmos Sánchez L, Cardosa Benet JJ, et al. Holmium YAG Photocoagulation: Safe and Economical Alternative to Transurethral Resection in Small Nonmuscle-Invasive Bladder Tumors. J Endourol 2017;31:674-8.
DOI: https://doi.org/10.1089/end.2017.0154
Green DA, Rink M, Cha EK, et al. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. BJU Int. 2013; 111:E78-84.
DOI: https://doi.org/10.1111/j.1464-410X.2012.11454.x
Leonardi R, Vecco F, Iacona G, et al. TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting. Arch Ital Urol Androl 2023;95:11171.
DOI: https://doi.org/10.4081/aiua.2023.11171
Ströck V, Holmäng S. Is bladder tumour fulguration under local anaesthesia more painful than cystoscopy only? Scand J Urol 2020;54:277-80.
DOI: https://doi.org/10.1080/21681805.2020.1776768
Meeks JJ, Herr HW. Office-based management of nonmuscle invasive bladder cancer. Urol Clin North Am 2013;40:473-9.
DOI: https://doi.org/10.1016/j.ucl.2013.07.004
O'Neil BB, Lowrance WT. Office-based Bladder Tumor Fulguration and Surveillance: Indications and Techniques. Urol Clin North Am 2013;40:175-82.
DOI: https://doi.org/10.1016/j.ucl.2013.01.007
Vitug C, Lajkosz K, Chavarriaga J, et al. Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer. BJU Int 2024;133:289-296.
DOI: https://doi.org/10.1111/bju.16269
Al Hussein Al Awamlh B, Lee R, Chughtai B, Donat SM, et al. A cost-effectiveness analysis of management of low risk non-muscle-invasive bladder cancer using office-based fulguration. Urology 2015;85:381-6.
DOI: https://doi.org/10.1016/j.urology.2014.09.041
Wong KA, Zisengwe G, Athanasiou T, et al. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int 2013;112:561-7.
DOI: https://doi.org/10.1111/bju.12216
Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014;66:253-62.
DOI: https://doi.org/10.1016/j.eururo.2014.01.006
Pedersen GL, Erikson MS, Mogensen K, et al. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Lowgrade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol 2023;83:125-30.
DOI: https://doi.org/10.1016/j.eururo.2022.08.012
Halstuch D, Lotan P, Karchever I, et al. Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer. Clin Genitourin Cancer 2023;21:e320-e5.
DOI: https://doi.org/10.1016/j.clgc.2023.03.007
Malinaric R, Mantica G, Lo Monaco L, et al. The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know? Int J Environ Res Public Health 2022;19:9648.
DOI: https://doi.org/10.3390/ijerph19159648
How to Cite
Leonardi, R., Ambrosini, F., Cafarelli, A., Calarco, A., Colombo, R., Tuzzolo, D., De Marco, F., Ferrari, G., Ludovico, G., Pecoraro, S., De Cobelli, O., Terrone, C., & Mantica, G. (2024). Office-based management of Non-Muscle Invasive Bladder Cancer (NMIBC): A position paper on current state of the art and future perspectives. Archivio Italiano Di Urologia E Andrologia, 96(1). https://doi.org/10.4081/aiua.2024.12404
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.